Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
The natural killer (NK) and lymphokine-activated killer (LAK) cell activities of peripheral blood lymphocytes from chronic myeloid leukemia (CML) patients in remission and from healthy donors have been studied. Regression analysis to compare both cytotoxic responses in individual donors and the frequency of LAK cell precursors was also carried out. About 42% of CML patients in remission showed low NK activity (less than the mean percentage NK activity of healthy donors--2 SD) and were categorised as low NK responders. The stage of remission or the drugs used to bring about remission did not influence the NK status. The LAK activity of low NK as well as normal NK responder CML patients was significantly low against the NK-sensitive K562 cell line and the NK-resistant VIP (melanoma) and T-24 (bladder carcinoma) tumor targets, as assessed by linear regression analysis. Allogeneic leukemic cells were more resistant to killing, especially by patients' LAK cells. The frequency analysis of LAK cell precursors revealed a significant reduction in the LAK cell progenitor frequency in CML patients in remission.
Rajaram
N
N
Immunology Division, Tata Memorial Centre, Bombay, India.
Tatake
R J
RJ
Advani
S H
SH
Naik
S L
SL
Gangal
S G
SG
D000293:Adolescent; D000328:Adult; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007111:Immunity, Cellular; D007113:Immunity, Innate; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D008875:Middle Aged; D012044:Regression Analysis